This early phase I trial evaluates the use of [18F]3F-PHPG PET/CT in imaging patients with neuroendocrine tumors. Diagnostic procedures, such as [18F]3F-PHPG PET/CT, may help find and diagnose neuroendocrine tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT04510311.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To obtain basic information on the biodistribution and pharmacokinetics of fluorine F 18 3F-PHPG ([18F]3F-PHPG) in cancer patients with neuroendocrine tumors, such as pheochromocytoma, paraganglioma, etc.
SECONDARY OBJECTIVE:
I. To compare the diagnostic performance of [18F]3F-PHPG to in cancer patients with neuroendocrine tumors with the Food and Drug Administration (FDA) approved radiopharmaceuticals [123I]metaiodobenzylguanidine ([123I]MIBG; trade name AdreView) and Gallium Ga 68-DOTA-TATE ([68Ga]DOTA-TATE) (trade name Netspot).
OUTLINE:
Patients receive [18F]3F-PHPG intravenously (IV). Patients undergo positron emission tomography (PET)/computed tomography (CT) over 25-40 minutes at 90 minutes and 180 minutes after receiving [18F]3F PHPG.
After completion of study intervention, patients are followed up at 24 hours and 30 days.
Lead OrganizationUniversity of Michigan Comprehensive Cancer Center
Principal InvestigatorDavid M. Raffel
